Monopar Therapeutics appoints new board member

Monopar Therapeutics Inc . (NASDAQ:MNPR), a pharmaceutical company with a market capitalization of $217 million and an impressive 519% return over the past year, announced today the resignation of Michael J. Brown from its Board of Directors, effective last Monday. Following this departure, the company has appointed Lavina Talukdar to the board on Wednesday.

Talukdar, who currently serves as Senior Vice President and Head of Investor Relations at Moderna Inc (BMV:MRNA)., brings over two decades of experience in investor relations, healthcare investments, and financial strategy to Monopar Therapeutics. Her previous roles include Senior Portfolio Manager at Abu Dhabi Investment Authority and Partner and Healthcare Equity Analyst at Lord Abbett & Co.

The Corporate Governance and Nominating Committee of Monopar Therapeutics, after reviewing Talukdar’s qualifications and confirming her independence as per Nasdaq Capital Market standards, recommended her appointment. Along with her board duties, Talukdar will serve on the Audit Committee, Compensation Committee, Corporate Governance and Nominating Committee, and the Plan Administration Committee until the next annual meeting of stockholders.

There are no reported arrangements or understandings between Talukdar and any other individuals in relation to her appointment, nor are there any family-related transactions that would require disclosure under SEC rules. She is set to receive the standard compensation package for non-employee directors at Monopar Therapeutics.

This announcement is based on a recent SEC filing by Monopar Therapeutics. The company, headquartered in Wilmette, IL, specializes in pharmaceutical preparations and operates under Delaware incorporation. With analyst price targets ranging from $37 to $72 and its next earnings report due March 25, investors seeking deeper insights can access additional analysis and 8 more exclusive tips through InvestingPro.

In other recent news, Monopar Therapeutics has announced the pricing of a new stock offering alongside a private placement of pre-funded warrants. The public offering includes 798,655 shares of common stock priced at $23.79 each, while the private placement comprises pre-funded warrants for 882,761 shares at $23.789 per warrant. Monopar aims to raise $40 million in gross proceeds from these transactions, which are expected to close around December 23, 2024, pending standard closing conditions. The funds are intended for general corporate purposes, including research and development, clinical trials, and working capital.

Additionally, Piper Sandler has initiated coverage on Monopar Therapeutics, assigning an Overweight rating and a price target of $72.00. The analysts at Piper Sandler see significant potential in Monopar’s therapeutic pursuits, including a radiotherapeutic targeting a novel oncology marker and a small molecule for Wilson disease. They expect key developments, such as the initial efficacy data for the radiopharmaceutical MNPR-101 and the filing of a New Drug Application for ALXN1840, to draw investor attention. These developments are anticipated to provide substantial upside to the current stock price.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.